Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 10 Carcinoma, Hepatocellular 5 Ovarian Neoplasms 4 Endometrial Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Cutaneous 3 Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Myelodysplastic Syndromes 2 Melanoma 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Anaplastic 2 Leukemia, Myeloid, Acute 2 Fallopian Tube Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Sarcoma 1 Resectable Intrahepatic Cholangiocarcinoma 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Papillary renal cell carcinoma, sporadic 1

Interventions

Cyclophosphamide 27 fludarabine 18 Rituximab 17 obinutuzumab 11 venetoclax 9 Bendamustine Hydrochloride 9 Lenalidomide 8 zanubrutinib 6 Prednisone 6 Doxorubicin 6 Blood Specimen Collection 6 pembrolizumab 5 fludarabine phosphate 5 Biopsy 5 ibrutinib 4 glofitamab 4 Vincristine 4 Trimethoprim, Sulfamethoxazole Drug Combination 4 Exercise 4 loncastuximab tesirine 3 gamma-Globulins 3 axicabtagene ciloleucel 3 acalabrutinib 3 Temozolomide 3 Surveys and Questionnaires 3 Palliative Care 3 Mycophenolic Acid 3 Methotrexate 3 Mesna 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma × Immunoglobulin G × Clear all

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Dana-Farber Cancer Institute

Phase 1 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡